SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on NASH Biomarkers 2017Opening lecture: A pathologist, a radiologist and a hepatologist walked into a bar- Brent Neuschwander-Tetri, MDView Slideset
SlidesetRespiDART 2018Discovery and development of novel and potent non-fusion inhibitors of RSV | Michael Rhodin, PhDView Slideset
SlidesetRespiDART 2018RV521: A new and potent RSV fusion inhibitor in clinical development | Stuart Cockerill, PhDView Slideset
SlidesetRespiDART 2018Plenary Lecture: Opportunities and Challenges for a Broadly Protective Influenza Vaccine | Gary Nabel, MDView Slideset
SlidesetRespiDART 2018Abstract: Non-targeted diagnosis of multiple viral infections by means of shotgun metagenomic using deep sequencing (#104) | Slim Fourati, PhDView Slideset
SlidesetRespiDART 2018Abstract: Evaluation of the therapeutic potential of antibody and T cell targeted immune responses towards RSV small hydrophobic protein (#105) | Genevieve WeirView Slideset
SlidesetRespiDART 2018Abstract: Risk factors for RSV severity in immunocompetent and immunocompromised adults presenting in an emergency department (#103) | Slim FouratiView Slideset
SlidesetRespiDART 20183D Human epithelial models to study respiratory virus pathogenesis | Samuel Constant, PhDView Slideset
SlidesetHIVRespiDART 2018Abstract: Structure-based prediction of influenza resistance mutations (#102) | Bryan CoxView Slideset
SlidesetHIVRespiDART 2018Abstract: SB 9200 is a novel broad-spectrum antiviral agent effective against both RSV and Flu (#101) | Diane SchmidtView Slideset
SlidesetHIVRespiDART 2018Difficulties and barriers in developing RSV polymerase inhibitors | Rachel Fearns, PhDView Slideset
